Higher AlphaB-Crystallin Levels Linked to Diabetic Retinopathy

Share this content:
Higher AlphaB-Crystallin Levels Linked to Diabetic Retinopathy
Higher AlphaB-Crystallin Levels Linked to Diabetic Retinopathy

WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- Vitreous levels of alphaB-crystallin are significantly higher in eyes of patients with proliferative diabetic retinopathy (PDR) compared to the eyes of controls without diabetes, according to a study published online Dec. 7 in Clinical & Experimental Ophthalmology.

Wei Chen, Ph.D., from the Affiliated Hospital of Nantong University in China, and colleagues assessed vitreous samples collected before vitrectomy from 46 eyes of 46 consecutive patients with PDR and 19 patients without diabetes mellitus who had vitrectomy for idiopathic macular hole. Enzyme-linked immunosorbent assay was used to measure concentrations of alphaB-crystallin and vascular endothelial growth factor (VEGF).

The researchers found that the vitreous level of alphaB-crystallin was significantly higher in patients with PDR versus controls (P < 0.0001), as was the vitreous concentration of VEGF (P < 0.0001). Similarly, the expression levels of both alphaB-crystallin and VEGF were significantly higher in eyes with active PDR than in those with inactive PDR.

"These results suggest a significant increase of alphaB-crystallin in the vitreous fluid of patients with PDR and present a crucial association between alphaB-crystallin and VEGF with angiogenic activity in PDR," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »